Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich ’s Ataxia

Friedreich’s Ataxia is a Rare, Progressive, Life-Shortening, Neuromuscular Disease that Affects Approximately 5,000 Patients in the United States Application Assigned a PDUFA Date of November 30, 2022 If Approved, Omaveloxolone Would...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news